Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
New inhalers would have near-zero Global Warming Potential propellant
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Subscribe To Our Newsletter & Stay Updated
